Cooley advised Kezar Life Sciences, a biotechnology company focusing on small-molecule therapeutics to treat unmet needs in autoimmunity and cancer, on its agreement to be acquired by Aurinia Pharmaceuticals, a biopharmaceutical company focused on developing therapies to people living with autoimmune diseases with high unmet medical needs, for $6.955 in cash per share of Kezar common stock, plus one non-transferable contingent value right.